- Home
- PRVA vs CDTX Comparison
PRVA vs CDTX Comparison
Compare PRVA & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRVA
- CDTX
- Stock Information
- Founded
- PRVA 2007
- CDTX 2012
- Country
- PRVA United States
- CDTX United States
- Employees
- PRVA N/A
- CDTX N/A
- Industry
- PRVA Retail: Computer Software & Peripheral Equipment
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRVA Technology
- CDTX Health Care
- Exchange
- PRVA Nasdaq
- CDTX Nasdaq
- Market Cap
- PRVA 3.1B
- CDTX 2.8B
- IPO Year
- PRVA 2021
- CDTX 2015
- Fundamental
- Price
- PRVA $24.78
- CDTX $102.77
- Analyst Decision
- PRVA Strong Buy
- CDTX Strong Buy
- Analyst Count
- PRVA 13
- CDTX 13
- Target Price
- PRVA $29.08
- CDTX $118.50
- AVG Volume (30 Days)
- PRVA 722.9K
- CDTX 938.8K
- Earning Date
- PRVA 11-06-2025
- CDTX 11-06-2025
- Dividend Yield
- PRVA N/A
- CDTX N/A
- EPS Growth
- PRVA N/A
- CDTX N/A
- EPS
- PRVA 0.11
- CDTX N/A
- Revenue
- PRVA $1,900,071,000.00
- CDTX N/A
- Revenue This Year
- PRVA $96.90
- CDTX N/A
- Revenue Next Year
- PRVA $1.02
- CDTX N/A
- P/E Ratio
- PRVA $225.32
- CDTX N/A
- Revenue Growth
- PRVA 12.05
- CDTX N/A
- 52 Week Low
- PRVA $18.51
- CDTX $12.74
- 52 Week High
- PRVA $26.49
- CDTX $121.21
- Technical
- Relative Strength Index (RSI)
- PRVA 49.81
- CDTX 54.83
- Support Level
- PRVA $25.67
- CDTX $102.19
- Resistance Level
- PRVA $26.12
- CDTX $113.00
- Average True Range (ATR)
- PRVA 0.66
- CDTX 6.48
- MACD
- PRVA -0.22
- CDTX -0.89
- Stochastic Oscillator
- PRVA 32.94
- CDTX 47.27
About PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.